A

    AstraZeneca PLC (AZN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $162.05
    -0.65 (-0.40%)

    Market Cap: $252.33B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    60%(24/40)
    Avg Surprise
    +0.83%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$1.28
    Range$1.25 - $1.31
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$1.30+1.7%
    60d ago$1.31+2.3%
    30d ago$1.31+2.3%
    7d ago$1.31+2.1%
    Current$1.28
    Revenue Consensus
    $16.1B
    Range$15.8B - $16.3B
    9 analysts
    Dec 31, 2026
    EPS Consensus$6.26
    Range$6.19 - $6.34
    3 analysts
    Revenue Consensus
    $16.9B
    Range$16.0B - $18.0B
    25 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$6.26---
    Sep 26EST
    		-$1.28---
    Jun 26
    		$2.63$2.50+5.20%Beat+232.9%
    Mar 26
    		$1.29$1.27+1.57%Beat+3.2%
    Dec 25
    		$2.12$2.18-2.75%Miss-14.5%
    Sep 25
    		$1.19$1.13+5.31%Beat+13.3%
    Jun 25
    		$0.79$0.88-10.23%Miss-24.0%
    Mar 25
    		$1.25$1.12+11.61%Beat+26.3%
    Mar 25
    		$2.48$2.25+10.22%Beat+140.8%
    Dec 24
    		$1.05$1.04+0.96%Beat+43.8%
    Sep 24
    		$1.04$1.03+0.97%Beat+19.5%
    Jun 24
    		$0.99$0.99+0.00%Beat-8.3%
    Mar 24
    		$1.03$0.95+8.42%Beat+7.3%
    Dec 23
    		$0.73$0.76-3.95%Miss+5.8%
    Sep 23
    		$0.87$0.82+6.10%Beat+3.6%
    Jun 23
    		$1.08$0.97+11.34%Beat+25.6%
    Mar 23
    		$0.96$0.82+17.07%Beat+1.1%
    Dec 22
    		$0.69$0.68+1.47%Beat-17.9%
    Sep 22
    		$0.84$0.75+12.00%Beat+55.6%
    Jun 22
    		$0.86$1.04-17.31%Miss+91.1%
    Mar 22
    		$0.95$1.15-17.39%Miss+15.9%
    Dec 21
    		$0.84$0.99-15.15%Miss+37.7%
    Sep 21
    		$0.54$0.91-40.66%Miss+17.4%
    Jun 21
    		$0.45$0.69-34.78%Miss-6.2%
    Mar 21
    		$0.82$0.96-14.58%Miss+54.7%
    Dec 20
    		$0.61$0.76-19.74%Miss+155.7%
    Sep 20
    		$0.46$0.48-4.17%Miss-8.0%
    Jun 20
    		$0.48$0.40+20.00%Beat+29.7%
    Mar 20
    		$0.53$0.49+8.16%Beat+17.8%
    Dec 19
    		$0.24N/AN/ABeat-70.8%
    Sep 19
    		$0.50$0.41+21.95%Beat+38.9%
    Jun 19
    		$0.37$0.31+19.35%Beat+5.7%
    Mar 19
    		$0.45$0.38+18.42%Beat+67.7%
    Dec 18
    		$0.82$1.02-19.99%Miss+25.6%
    Sep 18
    		$0.36$0.37-2.70%Miss-35.7%
    Jun 18
    		$0.35$0.30+16.67%Beat-20.5%
    Mar 18
    		$0.27$0.35-23.31%Miss-46.3%
    Dec 17
    		$0.65$0.56+16.07%Beat+6.6%
    Sep 17
    		$0.56$0.57-1.75%Miss-15.2%
    Jun 17
    		$0.44$0.42+4.76%Beat-
    Mar 17
    		$0.50$0.54-7.41%Miss-
    Dec 16
    		$0.61$0.55+10.91%Beat-
    Sep 16
    		$0.66$0.47+40.43%Beat-

    Dividends

    Dividend Metrics

    Yield1.30%
    Annual/Share$2.10
    Payout Ratio12.08%
    Frequency2
    Pay MonthsFeb, Mar, Sep

    Growth

    3Y CAGR+3.29%
    5Y CAGR+2.40%
    View AZN's full dividend history

    Key Metrics

    Valuation
    P/E Ratio22.41EV/EBITDA13.89x
    Price/FCF28.92xFCF Yield3.46%
    Profitability
    Profit Margin17.00%Operating Margin23.50%
    ROE22.00%ROIC14.92%
    Financial Health
    Debt/Equity0.59xInterest Coverage8.26x
    Current Ratio0.89xQuick Ratio0.67x
    Trading Statistics
    Beta0.21Avg Volume4.34M
    52-Week High$209.1152-Week Low$143.33

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$164.74
    SMA 20$161.68
    SMA 50$169.83
    SMA 200$182.34
    EMA 10$163.81
    EMA 20$164.01
    EMA 50$168.50
    EMA 200$174.79

    MACD

    Line: -0.97Signal: -1.72Hist: 0.74

    ADX

    ADX: 16.8+DI: 25.2-DI: 29.7

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down20.0
    PSAR$154.72

    Bollinger Bands

    Upper Band$169.66
    Lower Band$153.71
    %B Position987%(Upper)
    Band Width0.52

    RSI (14-Day)

    Neutral
    45.1

    Momentum Oscillators

    Stoch %K54.7
    Stoch %D65.6
    Williams %R-51.9
    ROC (10d)3.3%
    Momentum5.16
    CCI (20d)19.3
    MFI (14d)48.3

    Volatility Measures

    ATR (14d)$3.70(2.3%)
    StdDev (20d)3.99
    Hist Vol24.6%(Moderate)

    Volume Flow

    VWAP$162.58
    OBV95.2M
    AD Line163.6B
    CMF (20d)-0.127

    Volume Metrics

    Avg Vol (20d)3.7M
    Vol Ratio0.8x
    VWMA (20d)$161.12

    Pivot Points

    R3$166.13
    R2$164.83
    R1$163.77
    Pivot Point$162.47
    S1$161.41
    S2$160.11
    S3$159.05

    Advanced Oscillators

    TSI-5.98
    Ultimate Osc52.5
    KST-33.56

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$15.38B$15.29B$15.50B$15.19B$14.46B$13.59B$13.59B$14.89B$13.56B$12.94B$12.68B$12.02B
    Cost of Revenue$2.52B$2.68B$3.12B$2.80B$2.47B$2.24B$2.24B$2.73B$3.08B$2.18B$2.22B$2.31B
    Gross Profit$12.86B$12.61B$12.38B$12.39B$11.98B$11.35B$11.35B$12.17B$10.48B$10.76B$10.46B$9.72B
    Operating Expenses$9.70B$8.36B$9.41B$8.81B$8.48B$7.67B$7.67B$10.13B$8.38B$8.01B$7.35B$8.48B
    R&D$4.05B$3.49B$3.86B$3.66B$3.55B$3.16B$3.16B$4.68B$3.12B$3.01B$2.78B$3.07B
    SG&A$5.65B$4.92B$5.49B$5.08B$4.86B$4.49B$4.63B$5.41B$5.14B$4.93B$4.50B$5.37B
    Operating Income$3.16B$4.25B$2.98B$3.58B$3.51B$3.67B$3.67B$2.04B$2.11B$2.75B$3.12B$1.23B
    Interest Income$80.00M$73.00M$135.00M$85.00M$68.00M$84.00M$84.00M$64.00M$183.00M$0$0$0
    Interest Expense$435.00M$393.00M$472.00M$434.00M$439.00M$349.00M$349.00M$429.00M$457.00M$443.00M$413.00M$445.00M
    Income Before Tax$2.80B$3.91B$2.63B$3.24B$3.13B$3.40B$3.40B$1.67B$1.83B$2.40B$2.80B$897.00M
    Income Tax Expense$291.00M$833.00M$300.00M$709.00M$679.00M$481.00M$481.00M$166.00M$395.00M$469.00M$620.00M$-62,000,000
    Net Income$2.51B$3.08B$2.33B$2.53B$2.45B$2.92B$2.92B$1.50B$1.43B$1.93B$2.18B$960.00M
    EBITDA$5.16B$5.67B$4.61B$5.23B$4.96B$5.04B$5.04B$2.81B$4.10B$4.12B$4.47B$2.67B
    EBIT$3.23B$4.31B$3.10B$3.68B$3.57B$3.75B$3.75B$2.10B$2.29B$2.84B$3.21B$1.34B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about AZN

    Government Contracts

    Gov Obligations (TTM)
    $733852
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    103.1%
    Active Awards
    4
    New Awards (TTM)
    3
    Avg Remaining Term
    4.6 mo

    Top agency: Department of Veterans Affairs at 99.9% of trailing twelve month obligations across 2 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26026F0055Department of Veterans AffairsDepartment of Veterans Affairs$1.26MDec 22, 2025
    36C24526N0739Department of Veterans AffairsDepartment of Veterans Affairs$104650Jul 21, 2026
    SPE2D026F0023Department of DefenseDefense Logistics Agency$500Nov 3, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    AstraZeneca climbs Tuesday, outperforms market

    AstraZeneca PLC (AZN) saw its shares rally by 3.02% on Tuesday, closing at £124.76. This strong performance occurred during a favorable trading session for the stock market, with the FTSE 100 Index also rising. Despite the gain, AstraZeneca's stock remains 20.70% below its 52-week high achieved in February.

    MarketWatch•8/25/26•
    Bullish

    AstraZeneca (AZN) lines up €2.55B in new Eurobonds

    AstraZeneca Finance LLC, a wholly-owned subsidiary of AstraZeneca PLC, has priced a €2.55 billion Eurobond offering as part of its long-term funding strategy. The offering, expected to close on September 1, 2026, comprises four tranches of fixed-rate notes with varying coupons and maturity dates between 2030 and 2038. The net proceeds are intended for general corporate purposes, with Barclays Bank PLC, Goldman Sachs International, and Morgan Stanley acting as joint book-running managers.

    Stock Titan•8/25/26•
    Neutral

    AstraZeneca PLC : Gets a Sell rating from Deutsche Bank

    Deutsche Bank has reiterated its "Sell" rating for AstraZeneca PLC, maintaining a target price of GBX 11500. The pharmaceutical company's stock currently shows a real-time estimate of 12,234.00 GBX with a slight 5-day change increase. AstraZeneca's net sales are predominantly from product sales, with oncology, cardiovascular, renal, and metabolic diseases being key treatment areas.

    www.marketscreener.com•8/25/26•
    Bearish

    AstraZeneca Prices €2.55 Billion Eurobond Offering to Strengthen Long-Term Funding

    AstraZeneca has priced a €2.55 billion multi-tranche Eurobond offering through its finance subsidiary to secure additional long-term funding with maturities between 2030 and 2038. The bonds, carrying coupons from 3.402% to 4.169%, are expected to be listed on the London Stock Exchange, and the net proceeds will be used for general corporate purposes. This move aims to reinforce the company's financial flexibility, supporting its investments in R&D, product launches, and commercial operations globally.

    Yahoo Finance UK•8/25/26•
    Somewhat-Bullish

    REG - AstraZeneca PLC - AstraZeneca prices a €2.55 billion bond offering

    AstraZeneca PLC announced that its subsidiary, AstraZeneca Finance LLC, successfully priced a €2.55 billion bond offering consisting of four tranches of Eurobonds. The offering, expected to close on September 1, 2026, aligns with the company's long-term funding strategy. The net proceeds will be used for general corporate purposes, and the notes will be listed on the UK Financial Conduct Authority's Official List and traded on the London Stock Exchange's Main Market.

    TradingView•8/25/26•
    Somewhat-Bullish

    Frequently Asked Questions About AZN

    What is AZN's current dividend yield?
    AstraZeneca PLC (AZN) has a current dividend yield of 1.30%.
    Does AZN pay dividends?
    Yes, AstraZeneca PLC pays dividends with a current yield of 1.30%.
    What is AZN's P/E ratio?
    AstraZeneca PLC has a price-to-earnings (P/E) ratio of 22.41.
    What is AZN's market cap?
    AstraZeneca PLC (AZN) has a market capitalization of $252.33B with a current stock price of $162.05.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In